Objective To study the curative effect and prognosis of 60 cases of anthracycline resistant breast cancer patients treated with docetaxel and vinorelbine Changchun.Methods 60 cases of patients with anthracene admissions ring resistant breast cancer From January, 2013 to October, 2016, in our hospital were researched.The control group were treated with docetaxel plus cisplatin, The observation group was treated with Changchun Red Sea combined with cisplatin, Two groups of patients with adverse reactions after treatment, quality of life scores, including physical function, psychological function, social function, mental function, treatment efficacy.Results After treatment, Incidence of adverse reactions in Observation group was less than the control group26.66%(8/30)vs 53.33%(16/30); Physical function, psychological function, social function, mental function score in Observation group (67.38 ±10.27、123.29 ±26.30、61.26 ±12.37、48.03 ±16.04) score were less than the control group (50.27 ±9.26、98.08 ±21.36、42.19 ±10.28、30.27 ±9.67) score(P<0.05).Remission rate of observation group 90.00% (27/30) was statistically higher than that in the control group 63.33%(19/30)( P<0.05).Conclusion Based on 60 cases of anthracycline resistant breast cancer were treated with vinorelbine and Changchun after docetaxel treatment of Changchun vinorelbine docetaxel treatment effect is better , can reduce the adverse reactions, is conducive to the prognosis of patients.%目的 比较长春瑞滨与多西他赛治疗蒽环类耐药60例乳腺癌患者的疗效及预后.方法 选取2013年1月~2016年10月宁波第五医院接诊的60例蒽环类耐药乳腺癌患者作为本次研究对象.对照组采用多西他赛联合顺铂进行治疗,观察组采用长春瑞滨联合顺铂进行治疗,观察2组患者治疗后不良反应情况,生活质量评分,包括躯体功能、心理功能、社会功能、精神功能,治疗疗效情况.结果 治疗后,观察组不良反应总发生率26.66%(8/30)小于对照组53.33%(16/30);观察组躯体功能、心理功能、社会功能、精神功能评分(67.38±10.27、123.29±26.30、61.26±12.37、48.03±16.04)分均优于对照组评分(50.27±9.26、98.08±21.36、42.19±10.28、30.27±9.67)分(P<0.05);观察组缓解率优于对照组90.00%vs63.33%(P<0.05).结论 通过对60例蒽环类耐药乳腺癌患者分别采用长春瑞滨与多西他赛治疗后研究得出,长春瑞滨治疗效果较多西他赛更佳,能够减少不良反应,有利于患者的预后.
展开▼
